The Rockefeller University

The Scripps Research Institute

Aaron Diamond Aids Research Center

Academia Sinica

David D Ho

Chi-Huey Wong

Yaoxing Huang

Moriya Tsuji

Jian Yu

Masakazu Fujio

Xiangming Li

Douglass Wu

Alice L Yu

Ruijiang Song

Ming Wei Chen

Ting-Jen Rachel Cheng

Craig Stuart Pace

Rachel Tj Cheng

Doug Wu

Xin Yao

Sharon R Lewin

Linqi Zhang

Leondios Kostrikis

The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.

Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics

Provided are tri-specific fusion antibodies created to target multiple epitopes of the Human Immunodeficiency Virus (HIV). The fusion antibodies provide improved potency and breadth against HIV as compared to monospecific and bispecific antibodies, and additionally provide a high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

Tri-specific antibodies for HIV therapy

In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Bispecific HIV-1-neutralizing antibodies

Bispecific HIV-1 neutralizing antibodies

Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.

Glycan-modified anti-CD4 antibodies for HIV prevention and therapy

Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity

This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.

Glycolipids and analogues thereof as antigens for NKT cells

This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.

Flu vaccines and methods of use thereof

This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.

Glycolipids and analogues thereof as antigens for NK T cells

Methods for identifying genetic sequences useful as genomic equivalent markers for organisms are described. The method involves determining the ratio of the absolute number of copies of wild type and mutant amplicons in a number of samples from organisms heterozygous for the mutation. After establishing the number of copies of a particular genetic sequence per genome, the sequence may be used as a measure of the number of genomes per sample, in order to normalize the analysis of another target sequence to abundance per cell. By way of example, the CCR5 gene was shown to be present at 2 copies per genome, and used to measure the number of copies per cell of HIV-1 provirions, human herpesvirus-8, and &agr; deletion circles, a measure of recent thymic emigrants for assessing immune reconstitution. The genomic equivalent marker may be use to identify other genomic equivalent markers based on their copy number in proportion to a previously established marker; by way of example the copy number of the &bgr;-actin gene was found to be 16 copies per genome. The genomic equivalent marker may also be use to determine number of cells in a sample, such as from a tissue sample.

Methods for identifying genomic equivalent markers and their use in quantitating cells and polynucleotide sequences therein

Growing community of inventors

New York, NY, United States of America

David D Ho